3.82
-0.23(-5.68%)
Currency In USD
Previous Close | 4.05 |
Open | 3.88 |
Day High | 3.98 |
Day Low | 3.58 |
52-Week High | 75.6 |
52-Week Low | 3.12 |
Volume | 133,036 |
Average Volume | 227,580 |
Market Cap | 2.73M |
PE | -0.12 |
EPS | -30.6 |
Moving Average 50 Days | 4.93 |
Moving Average 200 Days | 8.43 |
Change | -0.23 |
If you invested $1000 in Oragenics, Inc. (OGEN) 10 years ago, it would be worth $4.75 as of July 01, 2025 at a share price of $3.82. Whereas If you bought $1000 worth of Oragenics, Inc. (OGEN) shares 5 years ago, it would be worth $77.64 as of July 01, 2025 at a share price of $3.82.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium
GlobeNewswire Inc.
Jun 10, 2025 12:30 PM GMT
SARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced that Greg Gironda, Head of Business Development, will
Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split
GlobeNewswire Inc.
May 28, 2025 11:00 AM GMT
SARASOTA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company advancing innovative treatments for brain-related health conditions, today announced that its Board of Director
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
GlobeNewswire Inc.
May 13, 2025 12:30 PM GMT
SARASOTA, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that it has received approval from the Hum